• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bard touts data from Lutonix head-to-head study against MDT's In.Pact

February 12, 2016 By Fink Densford

C.R. BardC.R. Bard (NYSE:BCR) subsidiary Bard Peripheral Vascular touted results showing no significant difference in a study pitting its Lutonix DCB against Medtronic‘s (NYSE:MDT) In.Pact DCB in treating patients with complex femoropopliteal lesions.

Clinical data from the investigator-sponsored retrospective, single-center study was presented during the Leibzig International Course in Leipzig, Germany last month.

The study reported no statistically significant difference between Lutonix and In.Pact patients at 18 months in rates of target lesion revascularization and sustained clinical improvement. Clinical improvement was measured by improvement in Rutherford class from baseline or prior to the DCB treatment, the company said.

“These single-center results, like others before, show that real-world patients are benefiting from drug-coated balloon technology; and furthermore, the study indicates that there is no significant difference in the need for revascularization following treatment with either of these two DCBs,” Dr. Dierk Scheinert of Germany’s University of Leipzig said in a press release.

In total, data from the treatment of 575 limbs were included in the study, with 398 treated with Medtronic’s In.Pact and 177 treated with the Lutonix. Lutonix patients demonstrated a 73.1% freedom from TLR rate at 18 months, compared with a 74.8% rate for those treated with the In.Pact.

Lutonix patients reported a 66.4% rate of Rutherford class improvements at 18 months, while those treated with the In.Pact reported a 59.5% rate of improvement.

Last October, Bard released 2-year results from a small group of patients in a real-world registry study of its Lutonix drug-eluting balloon at the annual Transcatheter Cardiovascular Therapeutics conference in San Franscisco.

Bard said the Lutonix 035 device showed a 94.3% rate of freedom from target lesion revascularization in 631 patients at 12 months. A smaller group of 170 patients who were early enrollees in the study showed a 93.0% rate of TLR freedom at 24 months, Murray Hill, N.J.-based Bard said. Last June, 2-year data from Bard’s Levant 2 trial showed an 82% TLR freedom rate.

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: C.R. Bard

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS